New Peer Reviewed Article Demonstrates SilcsBio, LLC’s Performance Baltimore, Maryland, 4 November 2016 Recently published research has found that SilcsBio’s product, single-step free energy perturbation (SSFEP), demonstrated equal or more accurate results than standard free energy perturbation (FEP) but a thousand times faster. Additionally, SilcsBio’s site-identification by ligand competitive saturation (SILCS) product yielded relative free[…]
FOR IMMEDIATE RELEASE: July 7, 2016 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives Phase II NIH SBIR Funding Baltimore, Maryland: SilcsBio, LLC announced today a $1.3 million funding award from the National Institute of Health to develop new computer aided drug design (CADD) software. CADD software enables pharmaceutical companies to[…]
Check out this video to understand more about SilcsBio!
SilcsBio has exclusive rights to use U.S. and foreign patents pending by the University of Maryland, Baltimore. Patents include: U.S. Patent Application 13/265,568, titled “Method for binding site identification by molecular dynamics simulation (SILCS: Site Identification by Ligand Competitive Saturation),” published as US 2012/0053067.